Page last updated: 2024-08-16

thalidomide and carfilzomib

thalidomide has been researched along with carfilzomib in 109 studies

Research

Studies (109)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (2.75)	29.6817
2010's	90 (82.57)	24.3611
2020's	16 (14.68)	2.80

Authors

Authors	Studies
Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Lonial, S	1
Jagannath, S	1
Stewart, AK	2
Schots, R	1
Hata, H	1
Appel, A	1
Niesvizky, R	1
Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Nordgren, B; Stockerl-Goldstein, K; Vesole, DH; Vij, R	1
Bladé, J; Dimopoulos, MA; Kastritis, E	1
Arima, N; Kawada, H	1
Badros, A; Khan, RZ	1
Rajkumar, SV	1
Siegel, D	1
Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F	1
Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF	1
Abe, M; Fujii, S	1
Mahindra, A; Saini, N	1
Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM	1
Lokhorst, HM; van de Donk, NW	1
Klánová, M; Špička, I	1
El-Amm, J; Tabbara, IA	1
Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M	1
Mateos, MV; Ocio, EM; San Miguel, JF	1
Orlowski, RZ	1
Lentzsch, S; Schecter, J	1
Cavallo, F; Genadieva-Stavric, S; Palumbo, A	1
Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I	1
Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jasielec, J; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Stockerl-Goldstein, K; Vesole, DH; Vij, R	1
Chen, SE; Highsmith, KN; Horowitz, S	1
Vij, R	1
Gentili, S; Lonial, S	1
Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L	1
Hobeika, L; Self, SE; Velez, JC	1
Kuroda, J	1
Asselbergs, E; Broyl, A; de Weerdt, O; Kersten, MJ; Lokhorst, H; Lonergan, S; Palumbo, A; Sonneveld, P; van der Holt, B; van Marwijk-Kooy, M; Vellenga, E; Zweegman, S	1
Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG	1
Ben-Yehuda, D; Bensinger, WI; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, AJ; Kukreti, V; Ludwig, H; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, GG; Minarik, J; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajkumar, SV; Rajnics, P; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Suvorov, A; Tonda, ME; Wang, M; Xing, B; Yang, X; Zojwalla, N	1
Lonial, S; Usmani, SZ	1
Colson, K	1
Bergsagel, PL; Buadi, F; Costa, LJ; Dueck, AC; Gano, K; Libby, EN; Mayo, A; Mikhael, JR; Nagi Reddy, SK; Reeder, CB; Stewart, AK	1
Bay, JO	1
Printz, C	1
Moreau, P; Touzeau, C	1
Anderson, KC	1
Aleman, A; Anand, P; Batra, V; Bednarz, U; Bilotti, E; Guerrero, L; Ivanovski, K; Mato, A; McBride, L; McNeill, A; Raucci, L; Richter, JR; Siegel, DS; Sims, T; Smith, J; Vesole, DH	1
Arthur, DC; Bhutani, M; Braylan, R; Burton, D; Calvo, KR; Carpenter, A; Carter, G; Choyke, P; Costello, R; Cunningham, SC; Faham, M; Figg, W; Gounden, V; Kazandjian, D; Kong, KA; Korde, N; Kurdziel, K; Kwok, M; Lamping, L; Landgren, O; Lindenberg, L; Mailankody, S; Manasanch, EE; Maric, I; Morrison, C; Mulquin, M; Peer, C; Roschewski, M; Sissung, TM; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wall, Y; Weng, L; Wu, P; Yuan, C; Zhang, Y; Zingone, A; Zuchlinski, D	1
Dimopoulos, MA; Palumbo, A; San-Miguel, J; Siegel, D; Sonneveld, P	1
Boise, LH; Kaufman, J; Lonial, S	1
Abonour, R; Bensinger, WI; Cohen, AD; Durie, BG; Gasparetto, C; Gomes, CL; Kaufman, JL; Lentzsch, S; Orlowski, RZ; Pascucci, N; Shah, JJ; Smith, DD; Stadtmauer, EA; Vogl, DT	1
Hazlehurst, L; Lynch, CC; Shay, G	1
Ito, S	1
Bolomsky, A; Ludwig, H; Schlangen, K; Schreiner, W; Zojer, N	1
Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W	1
Jung, CK; Jung, Y; Kang, SW; Kim, BG; Kim, TH; Lee, SE; Lim, JY; Min, CK; Park, E; Park, J; Won, KA	1
Biran, N; Duma, N; Richter, J; Siegel, D; Vesole, DH	1
Broijl, A; Sonneveld, P	1
Aggarwal, SK; Barber, BL; Benedict, Á; Campioni, M; Giannopoulou, A; Houisse, I; Jakubowiak, AJ; Panjabi, S; Tichy, E	1
Hogan, JJ; Weiss, BM	1
Avet-Loiseau, H; Ben-Yehuda, D; Bensinger, W; Dimopoulos, MA; Fonseca, R; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Kukreti, V; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, G; Minarik, J; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rosiñol, L; Siegel, D; Špička, I; Stewart, AK; Wang, M	1
Fan, L; Hu, C; Ma, X; Ran, X; Yu, H; Zou, Y	1
Buchanan, J; Cocks, K; Dimopoulos, MA; Hájek, R; Jakubowiak, AJ; Ludwig, H; Masszi, T; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Tonda, M; Xing, B; Yang, X; Zojwalla, N	1
Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E	1
Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R	1
Bhutani, M; Burton, D; Calvo, KR; Carter, G; Costello, R; de Larrea, CF; Figg, WD; Gil, LA; Kazandjian, D; Korde, N; Kwok, M; Lamping, L; Landgren, O; Manasanch, EE; Maric, I; Mulquin, M; Roschewski, M; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wu, P; Yuan, C; Zingone, A; Zuchlinski, D	1
Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Aljerian, K; Almukhlafi, TS; Almutairi, MM; Alshammari, M; Ansari, MA; Ansari, MN; Imam, F	1
Boccadoro, M; Bonello, F; Larocca, A; Salvini, M	1
Berenson, A; Berenson, JR; David, M; Eades, B; Eshaghian, S; Gottlieb, J; Halleluyan, R; Harutyunyan, NM; Nassir, Y; Spektor, TM; Swift, R; Udd, KA; Vardanyan, S; Wang, J	2
Boyd, KD; Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Henderson, R; Jackson, GH; Jenner, M; Jones, JR; Kaiser, MF; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Pratt, G; Russell, NH; Sigsworth, R; Striha, A; Williams, C	1
Agarwal, A; Bhutani, M; Chow, E; Friend, R; Usmani, SZ; Voorhees, PM	1
Rajan, AM; Rajkumar, SV	1
Landgren, O	1
Abouzaid, S; Chen, CC; Hussein, M; McGuiness, CB; Parikh, K; Purnomo, L; Wade, RL	1
Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rajnics, P; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A	1
Li, B; Li, G; Liu, Y; Sheng, Z; Wang, L	1
Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajnics, P; Ro, S; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A	1
Figg, WD; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Peer, CJ; Sissung, TM; Venzon, DJ	1
de Wit, E; Moreau, P	1
Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K	1
Abouzaid, S; Ailawadhi, S; Chandler, C; Guo, S; Mouro, J; Parikh, K; Pelligra, CG	1
Guo, H; Sun, X; Wang, B; Xu, W	1
Costello, C; Mikhael, JR	1
Sonneveld, P	1
Corvatta, L; Gentili, S; Offidani, M	1
Hashida, H; Hatano, K; Irie, K; Matsumoto, H; Mitsutake, A; Tsukada, N	1
Blaedel, J; DeCosta, L; Goldschmidt, H; Leleu, X; Mateos, MV; Mikhael, J; Obreja, M; San-Miguel, J; Szabo, Z; Zhou, L	1
Belotti, A; Bertazzoni, P; Boccadoro, M; Bringhen, S; Cafro, AM; De Paoli, L; Fanin, R; Gaidano, G; Liberati, AM; Lombardo, A; Mina, R; Palumbo, A; Patriarca, F; Rossi, G; Sonneveld, P; Spada, S; Troia, R	1
Abraham, I; Anwer, F; Iftikhar, A; Kapoor, V; Latif, A; McBride, A; Mushtaq, A; Riaz, IB; Zahid, U	1
Borsi, E; Cavo, M; Mancuso, K; Martello, M; Pantani, L; Rocchi, S; Santacroce, B; Tacchetti, P; Terragna, C; Zamagni, E	1
Tomlinson, R	1
Al-Harbi, MM; Al-Harbi, NO; Alanazi, AZ; Alhazzani, K; Aljerian, K; Alsanea, S; Belali, OM; Imam, F; Qamar, W	1
Bringhen, S; Engelhardt, M; Wäsch, R; Yong, K	1
Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J	1
Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C	1
Dew, A; Hill, E; Kazandjian, D	1
Lu, SX	1
Aryal, M; Chhabra, S; D'Souza, A; Dhakal, B; Ghose, S; Giri, S; Hamadani, M; Hari, PN; Janz, S; Narra, RK; Pathak, LK; Smunt, TL; Szabo, A	1
Daguenet, E; Fouillet, L; Guyotat, D; Laurent, B; Le Jeune, C; Sapet, M	1
Berenson, JR; Eades, B; Emamy-Sadr, M; Regidor, B; Spektor, TM; Swift, R; Tarhini, F	1
Bal, S; Costa, LJ; Giri, S; Godby, KN	1
Andriani, A; Annibali, O; Antolino, G; Cantonetti, M; Cimino, G; Coppetelli, U; De Rosa, L; De Stefano, V; di Toritto, TC; La Verde, G; Petrucci, MT; Piciocchi, A; Rizzo, M; Siniscalchi, A; Vozella, F; Za, T	1
Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K	1
Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D	1
Berenson, JR; Eades, B; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Schwartz, G; Spektor, TM; Swift, RA; Vescio, R; Yashar, D	1
Aslam, M; Gul, E; Jimenez-Zepeda, VH; Kardjadj, M; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D	1
Buadi, F; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, R; Gonsalves, W; Hayman, S; Hobbs, M; Hwa, Y; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Muchtar, E; Rajkumar, SV; Siddiqui, M; Vaxman, I; Warsame, R	1

Reviews

44 review(s) available for thalidomide and carfilzomib

Article	Year
A review on the treatment of multiple myeloma with small molecular agents in the past five years. European journal of medicinal chemistry, 2022, Feb-05, Volume: 229 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases	2022
Practical considerations for multiple myeloma: an overview of recent data and current options. Clinical lymphoma & myeloma, 2008, Volume: 8 Suppl 4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide	2008
Novel therapies for relapsed myeloma. Hematology. American Society of Hematology. Education Program, 2009 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide	2009
[Development of novel agents for multiple myeloma; now and the future]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:8 Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Discovery; Drug Therapy, Combination; Heterocyclic Compounds; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Thalidomide; Vorinostat	2011
Novel therapies in monoclonal gammopathies. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide	2012
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective. Advances in chronic kidney disease, 2012, Volume: 19, Issue:5 Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Thalidomide	2012
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs]. Nihon Jinzo Gakkai shi, 2012, Volume: 54, Issue:5 Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide	2012
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome	2012
Therapeutic strategies for the treatment of multiple myeloma. Discovery medicine, 2013, Volume: 15, Issue:83 Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide	2013
[Multiple myeloma]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:7 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Prognosis; Pyrazines; Thalidomide	2013
Emerging therapies in multiple myeloma. American journal of clinical oncology, 2015, Volume: 38, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Signal Transduction; Thalidomide	2015
Novel generation of agents with proven clinical activity in multiple myeloma. Seminars in oncology, 2013, Volume: 40, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrroles; Recurrence; Thalidomide; Treatment Outcome	2013
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Seminars in oncology, 2013, Volume: 40, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat	2013
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy. Current hematologic malignancy reports, 2013, Volume: 8, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide	2013
New approaches to management of multiple myeloma. Current treatment options in oncology, 2014, Volume: 15, Issue:2 Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome	2014
Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma. Pharmacotherapy, 2014, Volume: 34, Issue:9 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Survival Rate; Thalidomide; Treatment Outcome	2014
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma. Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25 Suppl 2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System Diseases; Oligopeptides; Pyrazines; Recurrence; Thalidomide; Venous Thromboembolism	2011
Relapsed and refractory multiple myeloma: new therapeutic strategies. Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome	2014
Pomalidomide for multiple myeloma. Expert review of hematology, 2014, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide	2014
[Current status of clinical trials of novel agents for multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Approval; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Pyrroles; Thalidomide; Vorinostat	2014
Current treatment landscape for relapsed and/or refractory multiple myeloma. Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome	2015
Novel drug combinations for the management of relapsed/refractory multiple myeloma. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14 Suppl Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Disease Progression; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide	2014
Treatment-related symptom management in patients with multiple myeloma: a review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide	2015
Multiple myeloma: from front-line to relapsed therapies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Humans; Methotrexate; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Randomized Controlled Trials as Topic; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Vincristine	2015
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:11 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Risk Factors; Thalidomide	2015
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. Journal of molecular medicine (Berlin, Germany), 2016, Volume: 94, Issue:1 Topics: Bone and Bones; Bone Marrow; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Tumor Microenvironment	2016
Treatment of relapsed and refractory multiple myeloma. Haematologica, 2016, Volume: 101, Issue:4 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Palliative Care; Plasma Cells; Precision Medicine; Proteasome Inhibitors; Recurrence; Thalidomide	2016
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. Clinical journal of the American Society of Nephrology : CJASN, 2016, 09-07, Volume: 11, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine	2016
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. Oncotarget, 2017, Jun-13, Volume: 8, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Prospective Studies; Salvage Therapy; Thalidomide	2017
Current treatments for renal failure due to multiple myeloma. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:16 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide	2016
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clinical journal of the American Society of Nephrology : CJASN, 2017, 01-06, Volume: 12, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib	2017
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. Expert review of anticancer therapy, 2017, Volume: 17, Issue:1 Topics: Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Survival Rate; Thalidomide	2017
Practical Considerations in Managing Relapsed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide	2017
Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials. European journal of haematology, 2017, Volume: 98, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome	2017
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. British journal of haematology, 2017, Volume: 179, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Oligopeptides; Panobinostat; Proteasome Inhibitors; Recurrence; Thalidomide	2017
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. Annals of hematology, 2018, Volume: 97, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prospective Studies; Proteasome Inhibitors; Recurrence; Survival Analysis; Thalidomide	2018
Management of multiple myeloma in the relapsed/refractory patient. Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1 Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide	2017
Triplet vs. doublet drug regimens for managing multiple myeloma. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Glycine; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oligopeptides; Stem Cell Transplantation; Thalidomide	2018
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Critical reviews in oncology/hematology, 2018, Volume: 125 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Treatment Outcome	2018
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future. Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment	2020
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future! Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Risk Factors; Survival Analysis; Thalidomide; Transplantation, Autologous	2020
Modern treatments and future directions for newly diagnosed multiple myeloma patients. Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Survival Analysis; Thalidomide; Transplantation, Autologous	2020
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. Cancer, 2020, 06-15, Volume: 126, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome	2020
New regimens and directions in the management of newly diagnosed multiple myeloma. American journal of hematology, 2021, 03-01, Volume: 96, Issue:3 Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Clinical Trials as Topic; Disease Management; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Protease Inhibitors; Randomized Controlled Trials as Topic; Risk; Thalidomide; Therapies, Investigational	2021

Trials

19 trial(s) available for thalidomide and carfilzomib

Article	Year
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 2012, Aug-30, Volume: 120, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Hypophosphatemia; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Thalidomide; Transplantation, Autologous; Treatment Outcome	2012
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Thalidomide; Treatment Outcome	2013
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood, 2013, Oct-31, Volume: 122, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome	2013
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood, 2014, Aug-07, Volume: 124, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome	2014
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood, 2015, Jan-15, Volume: 125, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Prognosis; Remission Induction; Survival Rate; Thalidomide; Young Adult	2015
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England journal of medicine, 2015, Jan-08, Volume: 372, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide	2015
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. British journal of haematology, 2015, Volume: 169, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Thalidomide; Treatment Outcome	2015
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. British journal of haematology, 2015, Volume: 171, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Rate; Thalidomide; Vorinostat	2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA oncology, 2015, Volume: 1, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maryland; Middle Aged; Multiple Myeloma; National Institutes of Health (U.S.); Neoplasm, Residual; Oligopeptides; Pilot Projects; Proteasome Inhibitors; Risk Factors; Thalidomide; Time Factors; Treatment Outcome; United States	2015
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood, 2015, Nov-12, Volume: 126, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Pneumonia; Pulmonary Embolism; Recurrence; Thalidomide; Time Factors	2015
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood, 2016, 09-01, Volume: 128, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Risk Factors; Survival Rate; Thalidomide	2016
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 11-10, Volume: 34, Issue:32 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Quality of Life; Recurrence; Thalidomide; Young Adult	2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood cancer journal, 2016, 12-09, Volume: 6, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Oligopeptides; Risk Factors; Thalidomide; Vorinostat	2016
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. British journal of haematology, 2017, Volume: 177, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide; Treatment Outcome	2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood cancer journal, 2017, 04-21, Volume: 7, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide; Treatment Outcome	2017
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. The oncologist, 2017, Volume: 22, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide	2017
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia, 2018, Volume: 32, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Follow-Up Studies; Humans; Multiple Myeloma; Oligopeptides; Prognosis; Survival Rate; Thalidomide	2018
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet (London, England), 2021, 06-19, Volume: 397, Issue:10292 Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Prospective Studies; Recurrence; Thalidomide	2021
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. Leukemia & lymphoma, 2022, Volume: 63, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide	2022

Other Studies

46 other study(ies) available for thalidomide and carfilzomib

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
New drugs in multiple myeloma and the significance of autologous stem cell transplants. Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Stem Cell Transplantation; Thalidomide	2009
Recent advances in myeloma treatment. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2011, Volume: 44, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide	2011
Drugs: More shots on target. Nature, 2011, Dec-14, Volume: 480, Issue:7377 Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine	2011
Novel therapeutics in multiple myeloma. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Vorinostat	2012
Role of carfilzomib in the treatment of multiple myeloma. Expert review of hematology, 2012, Volume: 5, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Multiple Myeloma; Oligopeptides; Peptide Hydrolases; Proteasome Inhibitors; Pyrazines; Thalidomide	2012
Initial success, frequent recurrence: tomorrow's multiple myeloma treatments and the value of subtype analysis. Interview with David Siegel. The American journal of managed care, 2012, Volume: 18, Issue:5 Spec No. Topics: Antineoplastic Agents; Cancer Vaccines; Humans; Lenalidomide; Managed Care Programs; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Secondary Prevention; Sequence Analysis, DNA; Thalidomide	2012
Multiple myeloma, version 1.2013. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat	2013
[Molecular targeting agents for multiple myeloma]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide	2012
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leukemia & lymphoma, 2014, Volume: 55, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide	2014
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:12 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide	2013
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica, 2014, Volume: 99, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Oligopeptides; Survival Analysis; Thalidomide; Treatment Outcome	2014
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC nephrology, 2014, Sep-30, Volume: 15 Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies	2014
[Carfilzomib in multiple myeloma relapses]. Bulletin du cancer, 2015, Volume: 102, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide	2015
New treatments highlighted for lymphoma and multiple myeloma. Cancer, 2015, May-15, Volume: 121, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Oligopeptides; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2015
Multiple myeloma: new uses for available agents, excitement for the future. Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:5 Suppl Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Proteasome Inhibitors; Thalidomide	2015
How I treat high-risk myeloma. Blood, 2015, Sep-24, Volume: 126, Issue:13 Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide	2015
[Novel agents in multiple myeloma treatment]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:10 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Oligopeptides; Protein Kinase Inhibitors; Signal Transduction; Thalidomide	2015
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. Journal of hematology & oncology, 2016, Mar-02, Volume: 9 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dexamethasone; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 2-Ring; Human Umbilical Vein Endothelial Cells; Humans; Multiple Myeloma; Neovascularization, Physiologic; Oligopeptides; Osteogenesis; Polycomb Repressive Complex 1; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thiazoles; Tumor Microenvironment	2016
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. PloS one, 2016, Volume: 11, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous	2016
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC cancer, 2016, Mar-24, Volume: 16 Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycine; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Thalidomide; Xenograft Model Antitumor Assays	2016
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series. Hematological oncology, 2017, Volume: 35, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Kidney Diseases; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide	2017
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. Journal of medical economics, 2016, Volume: 19, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Oligopeptides; Quality of Life; Quality-Adjusted Life Years; Recurrence; Thalidomide; United States	2016
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia & lymphoma, 2017, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Enzyme Activation; Female; Humans; Immunoglobulin Isotypes; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasm, Residual; Oligopeptides; Proteasome Endopeptidase Complex; Thalidomide; Treatment Outcome	2017
Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats. Toxicology mechanisms and methods, 2016, Volume: 26, Issue:9 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Dose-Response Relationship, Drug; Heart; Lipid Peroxidation; Male; MAP Kinase Signaling System; Myocardium; NF-kappa B; Oligopeptides; Oxidative Stress; Rats, Wistar; Thalidomide	2016
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Annals of hematology, 2017, Volume: 96, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Outpatient Clinics, Hospital; Retrospective Studies; Survival Rate; Thalidomide	2017
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Annals of hematology, 2017, Volume: 96, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome	2017
Treatment of newly diagnosed myeloma: Bortezomib-based triplet. Seminars in oncology, 2016, Volume: 43, Issue:6 Topics: Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Thalidomide	2016
Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status. Seminars in oncology, 2016, Volume: 43, Issue:6 Topics: Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Risk Factors; Thalidomide	2016
Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib. Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Retrospective Studies; Thalidomide	2017
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Polymorphism, Single Nucleotide; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2017
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. Clinical therapeutics, 2017, Volume: 39, Issue:10 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Humans; Models, Economic; Multiple Myeloma; Oligopeptides; Quality-Adjusted Life Years; Recurrence; Thalidomide; United States	2017
Therapy sequencing strategies in multiple myeloma: who, what and why? Future oncology (London, England), 2018, Volume: 14, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Thalidomide	2018
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:6 Topics: Adult; Brain; Brain Infarction; Dexamethasone; Female; Humans; Immunologic Factors; Ischemic Attack, Transient; Lenalidomide; Oligopeptides; POEMS Syndrome; Thalidomide	2018
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematological oncology, 2018, Volume: 36, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Thalidomide	2018
Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in Haematologica, 2018, Volume: 103, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide	2018
Multiple myeloma: Updated approach to management in 2018. Australian journal of general practice, 2018, Volume: 47, Issue:8 Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide	2018
Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries. International immunopharmacology, 2019, Volume: 66 Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Interleukin-10; Lipid Peroxidation; Male; Multiple Myeloma; NF-kappa B; Oligopeptides; Peroxidase; Rats; Rats, Inbred Strains; Thalidomide; Tumor Necrosis Factor-alpha; Vascular System Injuries	2019
Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update? Haematologica, 2019, Volume: 104, Issue:11 Topics: Dexamethasone; Humans; Multiple Myeloma; Oligopeptides; Thalidomide	2019
Hemophagocytic relapsed intramedullary plasmacytoma. International journal of hematology, 2020, Volume: 111, Issue:6 Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2020
[Proteinuria in multiple myeloma: Be careful to iatrogeny]. Bulletin du cancer, 2020, Volume: 107, Issue:4 Topics: Aged; Antineoplastic Agents; Autografts; Biopsy; Bortezomib; Dexamethasone; Female; Glomerulosclerosis, Focal Segmental; Humans; Iatrogenic Disease; Kidney; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteinuria; Thalidomide; Thrombotic Microangiopathies; Withholding Treatment	2020
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study. Annals of hematology, 2021, Volume: 100, Issue:4 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hypophosphatemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Thalidomide	2021
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. Annals of hematology, 2021, Volume: 100, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Oligopeptides; Progression-Free Survival; Thalidomide	2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. European journal of haematology, 2021, Volume: 107, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous	2021
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. Current oncology (Toronto, Ont.), 2022, 03-02, Volume: 29, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide	2022
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience. Blood cancer journal, 2023, 05-31, Volume: 13, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; POEMS Syndrome; Thalidomide	2023